In summary, we found that CCL27, a novel chemokine in the context of the bone marrow microenvironment, confers myeloma drug resistance to proteasome inhibitors by binding to stromal CCR10 and inducing IL-10, a myeloma survival factor. This evidence concerns the gene CCR10 and plasma cell myeloma.